Your basket is currently empty!
Tivozanib (Fotivda)
Tivozanib (Fotivda) is indicated for ‘the first line treatment of adult patients with advanced renal cell carcinoma (RCC) and for adult patients who are VEGFR and mTOR pathway inhibitor-naive following disease progression after one prior treatment with cytokine therapy for advanced RCC’.
Application- Tablet
Availability: UK